Bellomo Gianni
Gianni Bellomo, Department of Nephrology, San Giovanni Battista Hospital, 06034 Foligno, Italy.
World J Nephrol. 2013 May 6;2(2):17-25. doi: 10.5527/wjn.v2.i2.17.
A role for uric acid in the pathogenesis and progression of renal disease had been proposed almost a century ago, but, too hastily dismissed in the early eighties. A body of evidence, mostly accumulated during the last decade, has led to a reappraisal of the influence of uric acid on hypertension, cardiovascular, and renal disease. The focus of this review will be solely on the relationship between serum uric acid and renal function and disease. We will review experimental evidence derived from animal and human studies, evidence gathered from a number of epidemiological studies, and from the few (up to now) studies of uric-acid-lowering therapy. Some space will be also devoted to the effects of uric acid in special populations, such as diabetics and recipients of kidney allografts. Finally we will briefly discuss the challenges of a trial of uric-acid-lowering treatment, and the recent suggestions on how to conduct such a trial.
近一个世纪前就有人提出尿酸在肾脏疾病的发病机制和进展中起作用,但在80年代初就被草率地否定了。过去十年间积累的大量证据促使人们重新审视尿酸对高血压、心血管疾病和肾脏疾病的影响。本综述将仅聚焦于血清尿酸与肾功能及疾病之间的关系。我们将回顾来自动物和人体研究的实验证据、众多流行病学研究收集的证据,以及(截至目前)为数不多的降尿酸治疗研究。还将讨论尿酸在特殊人群(如糖尿病患者和肾移植受者)中的作用。最后,我们将简要讨论降尿酸治疗试验面临的挑战,以及近期关于如何开展此类试验的建议。